Long-Term Course of Humoral and Cellular Immune Responses in Outpatients After SARS-CoV-2 Infection.


Journal

Frontiers in public health
ISSN: 2296-2565
Titre abrégé: Front Public Health
Pays: Switzerland
ID NLM: 101616579

Informations de publication

Date de publication:
2021
Historique:
received: 29 06 2021
accepted: 25 08 2021
entrez: 14 10 2021
pubmed: 15 10 2021
medline: 21 10 2021
Statut: epublish

Résumé

Characterization of the naturally acquired B and T cell immune responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is important for the development of public health and vaccination strategies to manage the burden of COVID-19 disease. We conducted a prospective, cross-sectional analysis in COVID-19 recovered patients at various time points over a 10-month period in order to investigate how circulating antibody levels and interferon-gamma (IFN-γ) release by peripheral blood cells change over time following natural infection. From March 2020 till January 2021, we enrolled 412 adults mostly with mild or moderate disease course. At each study visit, subjects donated peripheral blood for testing of anti-SARS-CoV-2 IgG antibodies and IFN-γ release after SARS-CoV-2 S-protein stimulation. Anti-SARS-CoV-2 immunoglobulin G (IgG) antibodies were positive in 316 of 412 (76.7%) and borderline in 31 of 412 (7.5%) patients. Our confirmation assay for the presence of neutralizing antibodies was positive in 215 of 412 (52.2%) and borderline in 88 of 412 (21.4%) patients. Likewise, in 274 of 412 (66.5%) positive IFN-γ release and IgG antibodies were detected. With respect to time after infection, both IgG antibody levels and IFN-γ concentrations decreased by about half within 300 days. Statistically, production of IgG and IFN-γ were closely associated, but on an individual basis, we observed patients with high-antibody titres but low IFN-γ levels and vice versa. Our data suggest that immunological reaction is acquired in most individuals after natural infection with SARS-CoV-2 and is sustained in the majority of patients for at least 10 months after infection after a mild or moderate disease course. Since, so far, no robust marker for protection against COVID-19 exists, we recommend utilizing both, IgG and IFN-γ release for an individual assessment of the immunity status.

Identifiants

pubmed: 34646805
doi: 10.3389/fpubh.2021.732787
pmc: PMC8502872
doi:

Substances chimiques

Antibodies, Viral 0
Immunoglobulin G 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

732787

Informations de copyright

Copyright © 2021 Schiffner, Backhaus, Rimmele, Schulz, Möhlenkamp, Klemens, Zapf, Solbach and Mischnik.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

Nature. 2020 Aug;584(7821):457-462
pubmed: 32668444
Nat Commun. 2021 Jul 19;12(1):4383
pubmed: 34282139
N Engl J Med. 2021 Jul 1;385(1):90-92
pubmed: 33852796
Nat Rev Immunol. 2020 Sep;20(9):529-536
pubmed: 32728222
J Infect Dis. 2021 Jan 4;223(1):56-61
pubmed: 33128369
Nat Med. 2021 Jan;27(1):78-85
pubmed: 33184509
Signal Transduct Target Ther. 2020 Jul 2;5(1):112
pubmed: 32616709
Science. 2020 Oct 2;370(6512):89-94
pubmed: 32753554
Science. 2021 Feb 5;371(6529):
pubmed: 33408181
Lancet Healthy Longev. 2021 Jun;2(6):e362-e370
pubmed: 34104901
Scand J Work Environ Health. 2021 Jul 1;47(5):408-409
pubmed: 34003294
J Infect Dis. 2021 Jun 05;:
pubmed: 34089610
Infection. 2021 Aug;49(4):739-746
pubmed: 33689159
Turk J Emerg Med. 2018 Aug 07;18(3):91-93
pubmed: 30191186
Front Public Health. 2020 Sep 22;8:570543
pubmed: 33072707
Cell. 2020 Aug 20;182(4):843-854.e12
pubmed: 32673567
Nature. 2020 Oct;586(7830):594-599
pubmed: 32998157
Clin Infect Dis. 2020 Oct 09;:
pubmed: 33035306
Nat Med. 2020 Jun;26(6):845-848
pubmed: 32350462
Ann Intern Med. 2020 Sep 1;173(5):362-367
pubmed: 32491919
Cell. 2020 Nov 12;183(4):1024-1042.e21
pubmed: 32991844
Cell. 2020 Apr 16;181(2):271-280.e8
pubmed: 32142651
Nat Rev Immunol. 2020 Jul;20(7):392-394
pubmed: 32514035
Nature. 2021 Jul;595(7867):421-425
pubmed: 34030176

Auteurs

Julia Schiffner (J)

Center for Infection and Inflammation Research, University of Luebeck, Luebeck, Germany.
German Center for Infection Research (DZIF), Standort Hamburg-Borstel-Luebeck-Riems, Luebeck, Germany.
Health Protection Authority, Luebeck, Germany.

Insa Backhaus (I)

Medical Faculty, Centre for Health and Society, University Hospital, Institute of Medical Sociology, Heinrich-Heine-University, Düsseldorf, Germany.

Jens Rimmele (J)

Health Protection Authority, Luebeck, Germany.

Sören Schulz (S)

Health Protection Authority, Luebeck, Germany.

Till Möhlenkamp (T)

Health Protection Authority, Luebeck, Germany.

Julia Maria Klemens (JM)

Institute for Experimental Immunology, Affiliated to EUROIMMUN Medizinische Labordiagnostika AG, Luebeck, Germany.

Dorinja Zapf (D)

Institute for Experimental Immunology, Affiliated to EUROIMMUN Medizinische Labordiagnostika AG, Luebeck, Germany.

Werner Solbach (W)

Center for Infection and Inflammation Research, University of Luebeck, Luebeck, Germany.
German Center for Infection Research (DZIF), Standort Hamburg-Borstel-Luebeck-Riems, Luebeck, Germany.
Health Protection Authority, Luebeck, Germany.

Alexander Mischnik (A)

Health Protection Authority, Luebeck, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH